Cost is only one part of the problem though. The manufacturing at scale and ability to meet that volume reliably is an issue. The word has not gotten out far enough yet on validating the technology to make cost the only issue. Hopefully we get to that point in the next 12 months.
(1)
(0)
Decision Diagnostics Corp (DECN) Stock Research Links